Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by equities researchers at The Goldman Sachs Group from $200.00 to $225.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 56.16% from the stock’s current price.

Several other research analysts have also commented on the company. Stifel Nicolaus raised their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday. Finally, Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $193.43.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $144.08 on Thursday. The business’s 50-day moving average is $132.41 and its two-hundred day moving average is $132.36. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The firm has a market capitalization of $8.74 billion, a PE ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. Equities analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC boosted its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares during the period. Virtus ETF Advisers LLC boosted its position in shares of Ascendis Pharma A/S by 3.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after buying an additional 100 shares during the period. Legato Capital Management LLC lifted its position in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares during the period. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S in the third quarter worth approximately $30,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.